Perioperative nesiritide versus milrinone in high-risk coronary artery bypass graft patients

Annals of Pharmacotherapy

Volumn 41, Issue 3, 2007, Pages 427-432

  Brackbill, Marcia L ^a   Stam, M Denton ^b   Schuller Williams, Rebecca V ^c   Dhavle, Ajit A ^d  

^a SHENANDOAH UNIVERSITY   (United States)

^b Winchester Cardiothoracic and Vascular Surgeons   (United States)

^c CVS Inc   (United States)

^d Clinical Practice Integration   (United States)

Author keywords

Coronary artery bypass graft; Milrinone; Nesiritide

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLYCERYL TRINITRATE; LOOP DIURETIC AGENT; MILRINONE; NESIRITIDE; NEUROHORMONE;

ADULT; AGED; ARTICLE; BOLUS INJECTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART OUTPUT; HIGH RISK PATIENT; HORMONE RESPONSE; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; INCIDENCE; INTENSIVE CARE UNIT; INTRAOPERATIVE PERIOD; LENGTH OF STAY; MALE; MORTALITY; NATRIURESIS; PERIOPERATIVE PERIOD; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SURGICAL RISK; TREATMENT OUTCOME; VASODILATATION;

ADULT; AGED; AGED, 80 AND OVER; CARDIAC OUTPUT, LOW; CARDIOTONIC AGENTS; CORONARY ARTERY BYPASS; FEMALE; HOSPITALS, VOLUNTARY; HUMANS; INTENSIVE CARE UNITS; LENGTH OF STAY; MALE; MIDDLE AGED; MILRINONE; NATRIURETIC AGENTS; NATRIURETIC PEPTIDE, BRAIN; PERIOPERATIVE CARE;

EID: 34047233851     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1H500     Document Type: Article

References (14)

1. Hannan EL, Racz MJ, Walford G, et al. Predictors of readmission for complications of coronary artery bypass graft surgery. JAMA 2003;290: 773-80. DOI 10.1001/jama.290.6.773
2. O'Connor CM, Gattis WA, Uretsky BF, et al. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Rolan International Randomized Survival Trial (FIRST). Am Heart J 1999;138:78-86. DOI 10.1016/S0002-8703(99) 70250-4
3. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 1991;325:1468-75.
4. Felker GM, Benza RL, Chandler AB, et al. Heart failure etiology and response to milrinone in decompensated heart failure. J Am Coll Cardiol 2003;41:997-1003.
5. Product insert. Natrecor (nesitiride), revised April 2005. www.natrecor. com/pdf/natrecor_pi.pdf (accessed 2006 Oct 30).
6. Chen HH, Burnett JC. Natriuretic peptides in the pathophysiology of congestive heart failure. Curr Cardiol Rep 2000;2:198-205.
7. Abraham WT, Lowes BD, Ferguson DA, et al. Systemic hemodynamic, neurohormonal, and renal effects of steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. J Cardiac Fail 1998;4:37-44. DOI 10.1016/S1071-9164(98)90506-1
8. Sackner-Bernstein JD, Skopicki HA, Aaronson, KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 2005;111:1487-91. DOI 10.1161/01.CIR.0000159340.93220.E4
9. Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure. JAMA 2005;293:1900-5. DOI 10.1001/jama.293.15.1900
10. Moazami N, Damiano RJ, Bailey MS, et al. Nesiritide (BNP) in the management of postoperative cardiac patients. Ann Thorac Surg 2003; 75:1974-6. DOI 10.1016/S0003-4975(02)05009-9
11. Hebeler RF Jr, Oz MC. Effect of perioperative nesiritide administration on postoperative renal function and clinical outcomes in patients undergoing cardiothoracic surgery (poster 104, abstract 292). Presented at: 7th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke, Washington, DC, May 9, 2006.
12. Luber JM Jr. Perioperative nesiritide use is associated with decreased 180-day mortality in heart failure patients undergoing cardiothoracic surgery (poster 235). Presented at: Heart Failure Society of America 2006 Scientific Meeting, Seattle, WA, September 11, 2006.
13. Abraham WT, Adams KF, Fonarow GC, et al. In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the acute decompensated heart failure national registry (ADHERE). J Am Coll Cardiol 2005;46:57-64. DOI 10.1016/j.jacc.2005.03. 051
14. Arnold LM, Crouch MA, Carroll NV, et al. Outcomes associated with vasoactive therapy in patients with acute decompensated heart failure. Pharmacotherapy 2006;26:1078-85. DOI 10.152/phco.26.8.1078